Barclays’s Jasper Therapeutics JSPR Stock Holding History

Barclays’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$2	–	5253
2025 Q4	$2	Hold	1	–	–	﹤0.01%	5179
2025 Q3	$2	Hold	1	–	–	﹤0.01%	5434
2025 Q2	$6	Sell	1 -17,959	-100%	-$88.4K	﹤0.01%	5163
2025 Q1	$77.2K	Sell	17,960 -374	-2%	-$2.49K	﹤0.01%	4481
2024 Q4	$392K	Buy	18,334 +2,188	+14%	+$45.5K	﹤0.01%	3972
2024 Q3	$304K	Buy	16,146 +12,308	+321%	+$245K	﹤0.01%	4083
2024 Q2	$87.1K	Buy	+3,838	New	+$92.1K	﹤0.01%	3971
2023 Q3	–	Sell	-25	Closed	-$341	–	4652
2023 Q2	$341	Buy	+25	New	+$371	﹤0.01%	4398

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Barclays's JSPR Position: Q1 2026 in Review

Barclays sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Barclays first reported a position in JSPR in Q2 2023 and held it in 8 quarters. The position peaked at $392K in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Barclays reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
Barclays sold 1 Jasper Therapeutics share in Q1 2026, an estimated $2.
Barclays first reported a position in Jasper Therapeutics in Q2 2023 and held it in 8 quarters.
Barclays's Jasper Therapeutics position peaked at $392K in Q4 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.